 The primary goal of this investigator-initiated, small pilot study is to evaluate the safety and effectiveness of lenalidomide REVLIMID in CLE subjects using measurements such as the CLASI Cutaneous Lupus Activity and Severity Index. The study drug will be used in an off-label indication to treat 6 subjects, for whom lenalidomide REVLIMID will be provided at no cost by the drug manufacturer. Men and women over the age of 18, who have a biopsy proven diagnosis of refractory CLE and who have failed standard treatment with hydroxychloroquine for up to three months, will be included in the study. Secondarily, the study will evaluate the biologic effects of lenalidomide on pathogenic and immunologic mechanisms of the CLE disease process during the treatment period by collecting skin specimens biopsies and blood samples. 